Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPK-88006 in Healthy and Presumed MASH Participants
NCT07512427Phase 2Recruiting
- Sponsor
- OPKO Health
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of MOD-6031 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by OPKO Health. Started Jul 2026; status: recruiting.
02
Drugs
MOD-6031
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07512427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07512427.